SOS1-IN-14 |
| Catalog No.GC65873 |
SOS1-IN-14 is a potent, selective and orally active SOS1 inhibitor with an IC50 value of 3.9 nM. SOS1-IN-14 can be absorbed in the intestine via a P-glycoprotein-mediated efflux mechanism. SOS1-IN-14 can be used to research KRAS-mutated cancers. SOS1-IN-14 has better potent tumor suppression than BI-3406 (HY-125817).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2793405-20-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SOS1-IN-14 is a potent, selective and orally active SOS1 inhibitor with an IC50 value of 3.9 nM. SOS1-IN-14 can be absorbed in the intestine via a P-glycoprotein-mediated efflux mechanism. SOS1-IN-14 can be used to research KRAS-mutated cancers. SOS1-IN-14 has better potent tumor suppression than BI-3406 (HY-125817)[1].
SOS1-IN-14 (compound 13c) exhibits cellular SOS1 inhibition with an IC50 of 21 nM[1].
SOS1-IN-14 has certain inhibition for CYP2D6, CYP2C9, CYP2C8 and CYP3A4 with IC50s of 2.5 μM, 6.5 μM, 43.3 μM and 54.3 μM, respectively, indicating that it has a certain risk of drug-drug interaction[1].
SOS1-IN-14 (50 mg/kg; p.o.; qd) exhibits 83.0% tumor suppression in Mia-paca-2 pancreas xenograft mice tumor models[1].
SOS1-IN-14 shows a favorable pharmacokinetic profile with a bioavailability of 86.8% in beagles[1].
Pharmacokinetic Parameters of SOS1-IN-14 (compound 13c) in ICR mice, Sprague-Dawley rats and Beagle dogs[1].
| ICR Mice | Sprague-Dawley Rats | Beagle Dogs | |||
| Administration | p.o., 50 mg/kg | i.v., 2 mg/kg | p.o., 10 mg/kg | i.v., 2 mg/kg | p.o., 20 mg/kg |
| Tmax (h) | 0.5 | 0.08 | 3 | 0.08 | 2 |
| T1/2 (h) | 4.61 | 1.17 | 2.32 | 3.83 | 6.68 |
| Cmax (μg/mL) | 2670 | 1261 | 265 | 568 | 1840 |
| AUC0-24 (ng/mL.h) | 32300 | 970 | 1683 | 2962 | 25725 |
| CL (mL/min/kg) | / | 2068 | / | 11.3 | / |
| Vss (L/kg) | / | 2126 | / | 3.88 | / |
| F (%) | / | / | 34.5 | / | 86.8 |
| Kel (h-1) | 0.265 | / | / | / | / |
| MRT (h) | 4.67 | / | / | / | / |
| Animal Model: | BALB/c nude mice (KRAS G12C variant Mia-paca-2 xenograft models)[1] |
| Dosage: | 50 mg/kg |
| Administration: | p.o.; q.d., for 21 days |
| Result: | Exhibited 83.0% tumor suppression. Showed better potent tumor suppression than BI-3406 (HY-125817). |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *